Briefly, all individual samples were incubated with Human TruStain FcX (BioLegend, Cat
Efpeglenatide: originally developed by Sanofi, an exendin-4 analog with Fc fusion and PEGylation
Abbreviations T2D: Type 2 diabetes SA: Sleep apnea GLP-1RAs: Glucagon-like peptide-1 receptor agonists LDSC: Linkage disequilibrium score regression MR: Mendelian Randomization IVW: Inverse-variance weighted GWAS: Genome-wide association study eQTL: Expression quantitative trait loci SNP: Single nucleotide polymorphism HbA1c: Glycated hemoglobin A1c OSA: Obstructive sleep apnea CSA: Central sleep apnea AHI: Apneahypopnea index NAFLD: Non-alcoholic fatty liver disease RCT: Randomized controlled trials IV: Instrumental variables References Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al
Current clinical studies and trials have not shown a significant link between semaglutide and an increased risk of blood clots
Metabolic syndrome -basically heart disease, diabetes and their related conditions- are the top causes of death in the US and top costs to our health care system
